Monopar Therapeutics Inc (MNPR) — Cash Flow-to-Debt Ratio
Monopar Therapeutics Inc (MNPR) has a Cash Flow-to-Debt Ratio of -1.34x as of March 2026, meaning its operating cash flow of $-3.47 Million could theoretically repay -1% of its total liabilities ($2.59 Million) in one year. Explore Monopar Therapeutics Inc cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Monopar Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Monopar Therapeutics Inc across 11 annual periods. Also explore total assets of Monopar Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Monopar Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Monopar Therapeutics Inc. For market capitalisation and broader financial context, see MNPR market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.22x | $-12.20 Million | $2.89 Million | ▼ -246.4% |
| 2024 | -1.22x | $-6.40 Million | $5.25 Million | ▲ +72.7% |
| 2023 | -4.47x | $-7.86 Million | $1.76 Million | ▼ -94.1% |
| 2022 | -2.30x | $-7.23 Million | $3.14 Million | ▲ +50.2% |
| 2021 | -4.63x | $-7.32 Million | $1.58 Million | ▼ -16.8% |
| 2020 | -3.96x | $-4.66 Million | $1.18 Million | ▲ +4.9% |
| 2019 | -4.17x | $-3.02 Million | $724.16K | ▲ +42.3% |
| 2018 | -7.23x | $-2.89 Million | $399.55K | ▲ +14.2% |
| 2017 | -8.42x | $-2.63 Million | $311.87K | ▲ +54.5% |
| 2016 | -18.52x | $-1.19 Million | $64.51K | ▼ -114.9% |
| 2015 | -8.62x | $-636.33K | $73.84K | — |